Neuroendocrine Carcinoma Treatment Market Revenue to Cross US$ 2 Bn in 2024
On the back of surging monetary aids for clinical trials for developing innovative drugs, in tandem with increasing cancer caseloads, the neuroendocrine carcinoma treatment market is set for robust growth during 2019-2029. Realizing the prevalence of neuroendocrine carcinoma across the world, various government agencies such as the Food and Drug Administration (FDA) are granting easy approvals to oncology drugs for speedy disease treatment. This is further contributing to the global neuroendocrine carcinoma treatment market revenue, which will surpass US$ 2 Bn by 2024.
Frequently Asked Questions about Neuroendocrine Carcinoma Treatment Market
What drives the global neuroendocrine carcinoma treatment market?
Rising healthcare expenditure, coupled with expanding patient pool of cancer, will boost the global neuroendocrine carcinoma treatment market. The market is also expected to gain from increasing investments towards clinical trials for drug development.
Which end users are expected to contribute maximum revenue share during the forecast period?
Hospitals and clinics accounted for major revenue share, which constitutes nearly 70% of total neuroendocrine carcinoma treatment market revenue. In addition to this, oncology centers are exhibiting fast-paced adoption.
Which region will lead the global neuroendocrine carcinoma treatment market?
North America remains the largest shareholder in the global neuroendocrine carcinoma treatment market. The U.S. has emerged as a dominant region in the neuroendocrine carcinoma treatment market in terms of adoption. However, the market in Asia Pacific excluding Japan (APEJ) is expected to experience higher growth over the coming years.
Who are the major players in the neuroendocrine carcinoma treatment market?
Leading players in the neuroendocrine carcinoma treatment market include:
- AbbVie Inc.
- Advanced Accelerator Applications
- F. Hoffmann-La Roche
Which neuroendocrine carcinoma treatment type is expected to offer significant market growth potential over the next decade?
Used for treating indications such as vasoactive intestinal peptide, carcinoid tumors, and pituitary adenomas, somatostatin analogs are likely to observe relatively greater demand as compared to targeted therapy and chemotherapy, over the period of forecast (2019 to 2029).
Somatostatin Analogs Remain the Preferred Treatment Type
Somatostatin analogs will remain highly preferable for treating neuroendocrine carcinoma over the forecast timeframe, capturing over 3/5 share of total market revenue. Used for the treatment of indications such as vasoactive intestinal peptide, carcinoid tumors, and pituitary adenomas, the prominence of somatostatin analog therapy is expected to spread at a robust pace. Targeted therapies such as mTOR inhibitors and tyrosine kinase inhibitors for cancer treatment are also seeing a notable rise in their adoption, while chemotherapy is experiencing a relatively sluggish adoption rate.
North America - The Epicenter of Market Growth
Surging investments towards advanced healthcare infrastructure as well as favorable reimbursement policies would be the core drivers shaping the neuroendocrine carcinoma treatment market, in both, developed and developing regions. By capturing over one-third revenue share, North America continues to attract huge attention from stakeholders, and the regional market is poised to touch the US$ 1 Bn mark during the latter half of the foreseeable period. Players in the neuroendocrine carcinoma treatment market are also targeting Western Europe for lucrative returns. However, the neuroendocrine carcinoma treatment market in Asia Pacific (excluding Japan) is expected to reflect opportunistic growth potential in the coming years.
* This data is only a representation. Actual data may vary and will be available in report.
Indulging in Collaborations for Better Clinical Outcomes
In an effort to identify therapies for difficult-to-treat diseases, neuroendocrine carcinoma treatment market players are entering into strategic collaborations with research and academic institutes. These collaborative efforts for initiatives such as Cancer MoonShot 2020 and Precision Medicine Initiative (PMI) offer researchers with the required testing materials for the development of precision drugs to address rare illnesses. Combining technical resources with the vast knowledge base from research centers improves the quality of research and success rate, which is auguring well for market players.
Gastric neuroendocrine tumors most prevalent indication
Increasing prevalence of lung neuroendocrine tumors
Somatostatin analogs account for higher revenue share
Targeted therapy to witness healthy adoption
High adoption in hospitals
Application in clinics on the rise
How Growth will Unfold
As hospitalization of the patient is necessary to monitor the progress of therapy deployed during the treatment of neuroendocrine carcinoma, hospitals continue to be the prominent end user with a revenue share of over 40%. In 2019, the end user category was estimated to generate revenue worth US$ 645 Mn, with the value expected to double by the end of 2029. However, there are strong indications that clinics and oncology centers are likely to offer potential for bigger margins.
* This data is only a representation. Actual data may vary and will be available in report.Click Here To Know How The Growth Will Unfold
Custom Market Research Services
FMI offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.
Neuroendocrine Carcinoma Treatment Market Analysis 2019-2029
A recent market study published by Future Market Insights (FMI) on the neuroendocrine carcinoma treatment market includes global industry analysis for 2014-2018 and opportunity assessment for 2019-2029, and delivers a comprehensive assessment of the most important market dynamics. After conducting thorough research on the historical as well as current growth parameters of the neuroendocrine carcinoma treatment market, the growth prospects of the market are obtained with maximum precision.
Neuroendocrine Carcinoma Treatment Market Taxonomy
The global neuroendocrine carcinoma treatment market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader.
- Gastric Neuroendocrine Tumors
- Lung Neuroendocrine Tumors
- Pancreatic Neuroendocrine Tumors
- Appendiceal Neuroendocrine Tumors
- Somatostatin Analogs
- Targeted Therapy
- Oncology Centers
- Ambulatory Surgical Centers
- North America
- Latin America
- Western Europe
- Eastern Europe
The report initiates with the executive summary of the neuroendocrine carcinoma treatment market, which includes a summary of key findings and statistics of the market. It also includes the demand- & supply-side trends pertaining to the neuroendocrine carcinoma treatment market.
Readers can find the definition and a detailed segmentation of the neuroendocrine carcinoma treatment market in this chapter, which will help them understand the basic information about the neuroendocrine carcinoma treatment market. Along with this, comprehensive information pertaining to neuroendocrine carcinoma and their properties are provided in this section. This section also highlights the inclusions and exclusions, which helps the reader understand the scope of the neuroendocrine carcinoma treatment market report.
This chapter explains the key macro-economic factors that are expected to influence the growth of the neuroendocrine carcinoma treatment market over the forecast period. Along with the macroeconomic factors, this section also highlights the value chain, supply chain, forecast factors, Porter’s five forces analysis, and value chain analysis for the neuroendocrine carcinoma treatment market. Moreover, in-depth information about the market dynamics and their impact analysis on the market have been provided in the successive section.
This section includes the factors that have emerged as key successful factors and the strategies adopted by key market participants. This section also features the market specific developments to guide the readers in the strategic decision making process.
This section explains the global market value analysis and forecast for the neuroendocrine carcinoma treatment market during the forecast periods (2019-2029). This chapter includes a detailed analysis of the historical neuroendocrine carcinoma treatment market, along with an opportunity analysis of the future. Readers can also find the absolute $ opportunity for the current year (2019), and an incremental $ opportunity for the forecast period (2019-2029).
Based on disease indication, the neuroendocrine carcinoma treatment market is segmented into gastric neuroendocrine tumors, lung neuroendocrine tumors, pancreatic neuroendocrine tumors and appendiceal neuroendocrine tumors. In this chapter, readers can find information about the key trends and developments in the neuroendocrine carcinoma treatment market and market attractiveness analysis based on disease indication.
This chapter provides details about the neuroendocrine carcinoma treatment market based on the treatment type, and has been classified into somatostatin analogs, targeted therapy, and chemotherapy. In this chapter, readers can understand the market attractiveness analysis based on treatment type.
This chapter provides details about the neuroendocrine carcinoma treatment market based on the end users, and has been classified into hospitals, clinics, oncology centers, and ambulatory surgical centers. In this chapter, readers can understand the market attractiveness analysis based on end user.
This chapter explains how the neuroendocrine carcinoma treatment market will grow across various geographic regions such as North America, Latin America, Western Europe, Eastern Europe, APEJ, Japan, and Middle East & Africa (MEA).
This chapter includes a detailed analysis of the growth of the North America neuroendocrine carcinoma treatment market, along with a country-wise assessment that includes the U.S. and Canada. Readers can also find the pricing analysis, regional trends, and market growth based on treatment type and countries in North America.
This chapter provides the growth scenario of the neuroendocrine carcinoma treatment market in Latin American countries such as Brazil, Mexico and the Rest of Latin America. Along with this, assessment of the market across target segments has been provided.
Important growth prospects of the neuroendocrine carcinoma treatment market based on its end users in several countries such as Germany, France, Italy, Spain, the U.K., BENELUX and the Rest of Western Europe are included in this chapter.
In this chapter, Russia, Poland and Rest of Eastern Europe are prominent countries in the Eastern Europe region that are the prime subjects of assessment to obtain the growth prospects of the Eastern Europe neuroendocrine carcinoma treatment market. Readers can find detailed information about the growth parameters of the Eastern Europe neuroendocrine carcinoma treatment market during the forecast period of 2019-2029.
This chapter highlights the growth of the neuroendocrine carcinoma treatment market in APEJ by focusing on China, India, ASEAN, Australia & New Zealand and Rest of APEJ. This section also help readers understand the key factors that are responsible for the growth of the neuroendocrine carcinoma treatment market in APEJ region.
This chapter highlights the growth of the neuroendocrine carcinoma treatment market in Japan. This section also help readers understand the key factors that are responsible for the growth of the neuroendocrine carcinoma treatment market in Japan.
This chapter provides information about how the neuroendocrine carcinoma treatment market will grow in major countries in the MEA region such as GCC Countries, South Africa, and the Rest of MEA, during the forecast period of 2019-2029.
In this chapter, readers can find a comprehensive list of all prominent stakeholders in the neuroendocrine carcinoma treatment market, along with a detailed information about each company, which includes company overview, revenue shares, strategic overview, and recent company developments. Some of the market players featured in the report are Pfizer Inc., Novartis AG, Chiasma Inc., Ipsen, AbbVie Inc., Valeant Pharmaceuticals International Inc., Jubilant Life Sciences Ltd. and others.
This chapter includes a list of acronyms and assumptions that provides a base to the information and statistics included in the neuroendocrine carcinoma treatment market report.
This chapter help readers understand the research methodology followed to obtain various conclusions as well as important qualitative and quantitative information about the neuroendocrine carcinoma treatment market.
How the research was conducted?
- C - Level Executives
- Marketing Directors
- Product Managers
- Business Development Officers
- Production Managers
- Procurement Heads
- Sales Executives
- Raw Material Suppliers
- Industry Experts
- End Users
- Current Market Dynamics and Challenges
- Yesteryear Trends
- Market Characteristics
- Market Performance and Growth Quadrants
- Competition Structure and Market Structure
- Strategic Growth Initiatives
- Near-term and Long-Term Market Growth Prospects
- Market Segment Splits and Authenticity
- Opinions on Market Projections and Validity of Assumptions
- Industry Publications
- Journal of Oncology Research and Treatment
- Wiley Online Library
- US National Library of Medicine
- Industry Associations
- Carcinoid Cancer Foundation
- The European Neuroendocrine Tumor Society
- North American Neuroendocrine Tumor Society
- Carcinoid and Neuroendocrine Tumor Society, India
- Company Press Releases
- Annual Reports and Investor Presentations
- Research Papers
- Government Websites and Publications
- Trade Websites
- Scientific Research Publications
- International Conferences
Primary Interview Splits